Search company, investor...

Predict your next investment

Corporate Venture
ventures.mckesson.com

Investments

48

Portfolio Exits

13

Funds

1

Partners & Customers

4

Service Providers

1

About McKesson Ventures

McKesson Ventures is a strategic venture capital fund, to invest in early and growth stage companies addressing both current and emerging business challenges facing the healthcare industry. McKesson Ventures is actively making minority investments in companies that span a broad section of healthcare. The fund is focused on helping build businesses that are driving towards a stronger, more sustainable future for healthcare and will target companies that are both enabling and benefitting from the disruptive changes affecting the industry. These changes include increasing consumerism, emergence of alternate delivery models and the shift towards value based reimbursement models. These target companies will predominantly be pursuing high growth opportunities adjacent to or outside McKesson's current business.

Headquarters Location

1 Post Street

San Francisco, California, 94104,

United States

Want to inform investors similar to McKesson Ventures about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing McKesson Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find McKesson Ventures in 2 Expert Collections, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

P

Pharma Supply Chain

19 items

Research containing McKesson Ventures

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned McKesson Ventures in 2 CB Insights research briefs, most recently on Aug 17, 2022.

Latest McKesson Ventures News

Merck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort

Jan 18, 2023

News provided by Share this article Share this article Joining the cohort in Cambridge, MA, Perceiv AI will receive direct funding and mentorship from Merck, Northpond Ventures, and McKesson Ventures to advance its prognostic platform focused on multimodal data in neurodegenerative diseases. BOSTON, Jan. 17, 2023 /PRNewswire/ -  Perceiv AI  announced that the company has been selected by Merck ( NYSE: MRK ) for the inaugural Merck Digital Sciences Studio (MDSS) cohort, along with eight other early-stage biomedical startups from a pool of 152 applicants. The program started in November to fuel innovative digital technologies for drug discovery and development. "Being selected for the Merck MDSS program is a major accomplishment for Perceiv AI and a testament to the hard work and dedication of our team. This partnership is a huge step forward for us and we are grateful for this opportunity," said CEO and co-founder Dr. Christian Dansereau. "We are excited to work alongside such a renowned and respected company in the healthcare and life sciences industry and to use our cutting-edge AI technology to make a real impact in the field to advance pharma R&D innovation for clinical development, patient identification, clinical trial optimization, and trial de-risking." MDSS is a collaboration between Merck and the New Jersey Innovation Institute, with investments from the Merck Global Health Innovation Fund, Northpond Ventures, and McKesson Ventures. The accelerator provides direct investment from Merck, access to powerful Azure Cloud computing, and technology support provided by Microsoft for Startups. Additionally, participating companies are provided opportunities to collaborate with discovery and clinical scientists at Merck for pilots, where appropriate. Perceiv AI intends to expand upon its proprietary multimodal prognostic platform ForesightTM through the program. The ForesightTM platform, which integrates longitudinal clinical data with imaging and genetics to forecast disease progression, supports the development of prognostic biomarkers for neurological diseases, including Alzheimer's disease, for clinical trials and clinical use. Perceiv AI joins   Andson Biotech ,   Deep Forest Sciences , Gesund.ai ,   Magna Labs , IndyGeneUS AI ,   SciMar ONE ,   Stem Pharm , and   Pepper Bio  in the 10-month accelerator program. The program will begin with the company's exploration of where its technology can augment Merck's existing focus areas with the goal of transitioning into a pilot project with Merck. This announcement comes on the heels of Perceiv  AI 's closing of its financial round  at the end of last year. Along with strategic partners and investors like the one in this program, Perceiv AI will be able to further develop its ForesightTM platform. To learn more about Perceiv AI, please visit www.perceiv.ai . About Perceiv AI Perceiv AI is an AI-driven precision medicine company developing a powerful multimodal prognostic platform to forecast disease progression in age-related diseases like Alzheimer's. By providing a window into individual patients' disease progression, Perceiv AI aims to accelerate and de-risk the development of new therapies while enabling timelier diagnoses. About Merck Merck, also known as MSD outside of the United States and Canada, strives to be the premier research-intensive biopharmaceutical company through a diverse and inclusive global workforce. For over 130 years, Merck has been using the power of leading-edge science to deliver innovative health solutions to save and improve the health and wellness of people and animals worldwide with important medicines and vaccines. About New Jersey Innovation Institute New Jersey Innovation Institute (NJII), a 501c3 subsidiary of NJIT, combines the resources of the university, strong industry and government relationships, and proven methods to drive innovation and deliver transformative products and services that make a direct impact on the economy and the health and welfare of its participants. To achieve this, NJII is organized into four divisions that help turn ideas into workable solutions: healthcare, entrepreneurship, defense and homeland security, and professional and corporate education. More at   njii.com . About Northpond Ventures Northpond Ventures is a multi-billion-dollar science-driven venture capital firm based in Cambridge, MA; San Francisco, CA; and Bethesda, MD. Northpond has consistently been named one of the most active lead life science investors by both Crunchbase and Silicon Valley Bank. It is deeply engaged in the academic ecosystem, having founded The Laboratory for Bioengineering Research and Innovation at Harvard's Wyss Institute; launched the MIT-Northpond Program - Advancing Life Science & Engineering Innovation; and sponsored a prize for women entrepreneurs at MIT. It has led or co-led over 60 financings over the past several years and sits on the board of the vast majority of these businesses. Learn more at   npv.vc . SOURCE Perceiv AI

McKesson Ventures Investments

48 Investments

McKesson Ventures has made 48 investments. Their latest investment was in CancerIQ as part of their Series B on March 3, 2022.

CBI Logo

McKesson Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/3/2022

Series B

CancerIQ

$14M

Yes

15

2/7/2022

Series C

Koneksa

$45M

No

4

1/26/2022

Series A - II

Reimagine Care

$18.75M

Yes

6

1/19/2022

Series D

Subscribe to see more

Subscribe to see more

10

9/24/2021

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/3/2022

2/7/2022

1/26/2022

1/19/2022

9/24/2021

Round

Series B

Series C

Series A - II

Series D

Series B - II

Company

CancerIQ

Koneksa

Reimagine Care

Subscribe to see more

Subscribe to see more

Amount

$14M

$45M

$18.75M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

15

4

6

10

10

McKesson Ventures Portfolio Exits

13 Portfolio Exits

McKesson Ventures has 13 portfolio exits. Their latest portfolio exit was OncoHealth on May 09, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/9/2022

Acq - Fin

$99M

1

5/4/2022

Merger

$99M

1

8/18/2021

Acquired

$99M

33

10/6/2020

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

8/1/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/9/2022

5/4/2022

8/18/2021

10/6/2020

8/1/2020

Exit

Acq - Fin

Merger

Acquired

Reverse Merger

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

1

33

10

10

McKesson Ventures Acquisitions

1 Acquisition

McKesson Ventures acquired 1 company. Their latest acquisition was Saama Technologies on October 20, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/20/2021

Debt

$99M

$79.25M

Acq - Fin

14

Date

10/20/2021

Investment Stage

Debt

Companies

Valuation

$99M

Total Funding

$79.25M

Note

Acq - Fin

Sources

14

McKesson Ventures Fund History

1 Fund History

McKesson Ventures has 1 fund, including McKesson Ventures.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/10/2014

McKesson Ventures

1

Closing Date

12/10/2014

Fund

McKesson Ventures

Fund Type

Status

Amount

Sources

1

McKesson Ventures Partners & Customers

4 Partners and customers

McKesson Ventures has 4 strategic partners and customers. McKesson Ventures recently partnered with CVS Health on September 9, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

9/29/2022

Licensor

United States

McKesson Corporation - McKesson Corporation Extends Pharmaceutical Distribution Agreement With CVS Health

IRVING , Texas -- -- McKesson Corporation today announced that it has signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies , retail pharmacies and distribution centers through June 2027 .

1

6/23/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

6/13/2013

Client

United States

Subscribe to see more

Subscribe to see more

10

6/30/2010

Client

United States

Subscribe to see more

Subscribe to see more

10

Date

9/29/2022

6/23/2022

6/13/2013

6/30/2010

Type

Licensor

Partner

Client

Client

Business Partner

Country

United States

United States

United States

United States

News Snippet

McKesson Corporation - McKesson Corporation Extends Pharmaceutical Distribution Agreement With CVS Health

IRVING , Texas -- -- McKesson Corporation today announced that it has signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies , retail pharmacies and distribution centers through June 2027 .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

McKesson Ventures Service Providers

1 Service Provider

McKesson Ventures has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

McKesson Ventures Team

2 Team Members

McKesson Ventures has 2 team members, including current Senior Vice President, Managing Director, David Schulte.

Name

Work History

Title

Status

David Schulte

Senior Vice President, Managing Director

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

David Schulte

Subscribe to see more

Work History

Title

Senior Vice President, Managing Director

Subscribe to see more

Status

Current

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.